Clinician-Reported Impact of Germline Multigene Panel Testing on Cancer Risk Management Recommendations.

ABSTRACT:

Background

With increased adoption of multi-gene panel testing (MGPT) for hereditary cancer, management guidelines now include a wider range of predisposition genes. Yet little is known about whether MGPT results prompt changes to clinicians' risk management recommendations and whether those recommendations adhere to guidelines.

Methods

We assessed cancer risk management recommendations made by clinicians ordering MGPT for hereditary cancer at a diagnostic laboratory using an internet-based survey. We received paired pre- and posttest responses for 2172 patients (response rate = 14.3%). Unpaired posttest responses were received in 168 additional patients with positive results. All tests were 2-sided.

Results

Clinicians reported a change in risk management recommendati

SUBMITTER: Horton C 

PROVIDER: S-EPMC8904928 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature